Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion clinical trials

Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

This study is looking at a new combination of treatments for advanced lung cancer. It combines a new drug called OMTX705 with standard chemotherapy and another modern treatment to see how safe and effective it is for patients whose cancer has spread.